Literature DB >> 24735716

Distinguishing classical papillary thyroid microcancers from follicular-variant microcancers.

Surbhi Singhal1, Rebecca S Sippel1, Herbert Chen1, David F Schneider2.   

Abstract

BACKGROUND: Papillary thyroid microcarcinomas (mPTCs), tumors less than or equal to 1 cm, have been considered the same clinical entity as microfollicular-variant papillary thyroid microcarcinomas (mFVPTCs). The purpose of this study was to use population-level data to characterize differences between mFVPTC and mPTC.
MATERIALS AND METHODS: We identified adult patients diagnosed with mFVPTC or mPTC between 1998 and 2010 in the Surveillance, Epidemiology, and End Results database. Binary comparisons were made with the Student t-test and chi-squared test. Multivariate logistic regression was used to further analyze lymph node metastases and multifocality.
RESULTS: Of the 30,926 cases, 8697 (28.1%) were mFVPTC. Multifocal tumors occurred with greater frequency in the mFVPTC group compared with the mPTC group (35.4% versus 31.7%; P<0.01). Multivariate logistic regression indicated that patients with mFVPTC had a 26% increased risk of multifocality (odds ratio, 1.26; 95% confidence interval, 1.2-1.4; P<0.01). In contrast, lymph node metastases were nearly twice as common in the mPTC group compared with the mFVPTC group (6.8% versus 3.6%; P<0.01). Multivariate logistic regression confirmed that patients with mPTC had a 69% increased risk of lymph node metastases compared with patients with mFVPTC (odds ratio, 1.69; 95% confidence interval, 1.4-2.0; P<0.01).
CONCLUSIONS: Multifocality is not unique to classical mPTC and occurs more often in mFVPTC. The risk of lymph node metastases is greater for mPTC than mFVPTC. The surgeon should be aware of these features as they may influence the treatment for these microcarcinomas.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Follicular variant of papillary thyroid carcinoma; Lymph node metastases; Microcarcinoma; Multifocality; Papillary thyroid carcinoma; SEER; Thyroid cancer

Mesh:

Year:  2014        PMID: 24735716      PMCID: PMC4053495          DOI: 10.1016/j.jss.2014.03.032

Source DB:  PubMed          Journal:  J Surg Res        ISSN: 0022-4804            Impact factor:   2.192


  33 in total

Review 1.  Papillary carcinoma of thyroid: A 30-yr clinicopathological review of the histological variants.

Authors:  Alfred King-Yin Lam; Chung-Yau Lo; Karen Siu-Ling Lam
Journal:  Endocr Pathol       Date:  2005       Impact factor: 3.943

2.  Follicular variant of papillary carcinoma. Cytologic and histologic correlation.

Authors:  Z W Baloch; P K Gupta; G H Yu; M J Sack; V A LiVolsi
Journal:  Am J Clin Pathol       Date:  1999-02       Impact factor: 2.493

3.  Increasing incidence of thyroid cancer in the United States, 1973-2002.

Authors:  Louise Davies; H Gilbert Welch
Journal:  JAMA       Date:  2006-05-10       Impact factor: 56.272

4.  Classical and follicular variant of papillary thyroid carcinoma: a comparative study on clinicopathologic features and long-term outcome.

Authors:  Brian Hung-Hin Lang; Chung-Yau Lo; Wai-Fan Chan; Alfred King-Yin Lam; Koon-Yat Wan
Journal:  World J Surg       Date:  2006-05       Impact factor: 3.352

5.  Follicular variant of papillary thyroid carcinoma: clinical-pathological characterization and long-term follow-up.

Authors:  Philippe Hagag; Nir Hod; Esther Kummer; Mehrzad Cohenpour; Tifha Horne; Mordechai Weiss
Journal:  Cancer J       Date:  2006 Jul-Aug       Impact factor: 3.360

6.  Follicular variant of papillary thyroid carcinoma: a clinicopathologic study of a problematic entity.

Authors:  Jeffrey Liu; Bhuvanesh Singh; Giovanni Tallini; Diane L Carlson; Nora Katabi; Ashok Shaha; R Michael Tuttle; Ronald A Ghossein
Journal:  Cancer       Date:  2006-09-15       Impact factor: 6.860

7.  Independent clonal origins of distinct tumor foci in multifocal papillary thyroid carcinoma.

Authors:  Trisha M Shattuck; William H Westra; Paul W Ladenson; Andrew Arnold
Journal:  N Engl J Med       Date:  2005-06-09       Impact factor: 91.245

8.  Extracapsular invasion of lymph node metastasis. A good indicator of disease recurrence and poor prognosis in patients with thyroid microcarcinoma.

Authors:  H Yamashita; S Noguchi; N Murakami; M Toda; S Uchino; S Watanabe; H Kawamoto
Journal:  Cancer       Date:  1999-09-01       Impact factor: 6.860

9.  Diagnosis and therapeutic strategy for papillary thyroid microcarcinoma.

Authors:  Jen-Der Lin; Szu-Tah Chen; Tzu-Chieh Chao; Chuen Hsueh; Hsiao-Fen Weng
Journal:  Arch Surg       Date:  2005-10

10.  Clinical and histological characteristics of papillary thyroid microcarcinoma: results of a retrospective study in 243 patients.

Authors:  Elio Roti; Roberta Rossi; Giorgio Trasforini; Fiorenza Bertelli; Maria Rosaria Ambrosio; Luciano Busutti; Elizabeth N Pearce; Lewis E Braverman; Ettore C Degli Uberti
Journal:  J Clin Endocrinol Metab       Date:  2006-02-14       Impact factor: 5.958

View more
  4 in total

1.  Clinical characteristics and surgical resection of multifocal papillary thyroid carcinoma: 168 cases.

Authors:  Guomin Huang; Xiaofeng Tian; Yuhui Li; Fujian Ji
Journal:  Int J Clin Exp Med       Date:  2014-12-15

2.  Risk factors for central neck lymph node metastases in follicular variant vs. classic papillary thyroid carcinoma.

Authors:  Marco Raffaelli; Carmela De Crea; Luca Sessa; Guido Fadda; Celestino Pio Lombardi; Rocco Bellantone
Journal:  Endocrine       Date:  2018-05-16       Impact factor: 3.633

3.  Accounting for tissue heterogeneity in infrared spectroscopic imaging for accurate diagnosis of thyroid carcinoma subtypes.

Authors:  David Martinez-Marin; Hari Sreedhar; Vishal K Varma; Catarina Eloy; Manuel Sobrinho-Simões; André Kajdacsy-Balla; Michael J Walsh
Journal:  Vib Spectrosc       Date:  2016-09-16       Impact factor: 2.507

4.  The age threshold of the 8th edition AJCC classification is useful for indicating patients with aggressive papillary thyroid cancer in clinical practice.

Authors:  Krzysztof Kaliszewski; Dorota Diakowska; Łukasz Nowak; Beata Wojtczak; Jerzy Rudnicki
Journal:  BMC Cancer       Date:  2020-11-30       Impact factor: 4.430

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.